MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
29
10
2019
pubmed:
29
2
2020
medline:
5
5
2021
entrez:
29
2
2020
Statut:
ppublish
Résumé
Microsatellite instability (MSI) has emerged as a predictive biomarker for immune checkpoint inhibitor therapy. Cancer heterogeneity represents a potential obstacle for the analysis of predicitive biomarkers. MSI has been reported in pancreatic cancer, but data on the possible extent of intratumoral heterogeneity are lacking. To study MSI heterogeneity in pancreatic cancer, a tissue microarray (TMA) comprising 597 tumors was screened by immunohistochemistry with antibodies for the mismatch repair (MMR) proteins MLH1, PMS2, MSH2, and MSH6. In six suspicious cases, large section immunohistochemistry and microsatellite analysis (Bethesda panel) resulted in the identification of 4 (0.8%) validated MSI cases out of 480 interpretable pancreatic ductal adenocarcinomas. MSI was absent in 55 adenocarcinomas of the ampulla of Vater and 7 acinar cell carcinomas. MMR deficiency always involved MSH6 loss, in three cases with additional loss of MSH2 expression. Three cancers were MSI-high and one case with isolated MSH6 loss was MSS in PCR analysis. The analysis of 44 cancer-containing tumor blocks revealed that the loss of MMR protein expression was always homogeneous in affected tumors. Automated digital image analysis of CD8 immunostaining demonstrated markedly higher CD8 + tumor infiltrating lymphocytes in tumors with (mean = 685, median = 626) than without (mean = 227; median = 124) MMR deficiency (p < 0.0001), suggesting a role of MSI for immune response. Our data suggest that MSI occurs early in a small subset of ductal adenocarcinomas of the pancreas and that immunohistochemical MMR analysis on limited biopsy or cytology material may be sufficient to estimate MMR status of the entire cancer mass.
Sections du résumé
BACKGROUND
BACKGROUND
Microsatellite instability (MSI) has emerged as a predictive biomarker for immune checkpoint inhibitor therapy. Cancer heterogeneity represents a potential obstacle for the analysis of predicitive biomarkers. MSI has been reported in pancreatic cancer, but data on the possible extent of intratumoral heterogeneity are lacking.
METHODS
METHODS
To study MSI heterogeneity in pancreatic cancer, a tissue microarray (TMA) comprising 597 tumors was screened by immunohistochemistry with antibodies for the mismatch repair (MMR) proteins MLH1, PMS2, MSH2, and MSH6.
RESULTS
RESULTS
In six suspicious cases, large section immunohistochemistry and microsatellite analysis (Bethesda panel) resulted in the identification of 4 (0.8%) validated MSI cases out of 480 interpretable pancreatic ductal adenocarcinomas. MSI was absent in 55 adenocarcinomas of the ampulla of Vater and 7 acinar cell carcinomas. MMR deficiency always involved MSH6 loss, in three cases with additional loss of MSH2 expression. Three cancers were MSI-high and one case with isolated MSH6 loss was MSS in PCR analysis. The analysis of 44 cancer-containing tumor blocks revealed that the loss of MMR protein expression was always homogeneous in affected tumors. Automated digital image analysis of CD8 immunostaining demonstrated markedly higher CD8 + tumor infiltrating lymphocytes in tumors with (mean = 685, median = 626) than without (mean = 227; median = 124) MMR deficiency (p < 0.0001), suggesting a role of MSI for immune response.
CONCLUSIONS
CONCLUSIONS
Our data suggest that MSI occurs early in a small subset of ductal adenocarcinomas of the pancreas and that immunohistochemical MMR analysis on limited biopsy or cytology material may be sufficient to estimate MMR status of the entire cancer mass.
Identifiants
pubmed: 32108923
doi: 10.1245/s10434-020-08209-y
pii: 10.1245/s10434-020-08209-y
pmc: PMC7471097
doi:
Substances chimiques
MutL Protein Homolog 1
EC 3.6.1.3
MutS Homolog 2 Protein
EC 3.6.1.3
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3997-4006Commentaires et corrections
Type : ErratumIn
Références
J Cancer Res Ther. 2013 Jan-Mar;9(1):80-3
pubmed: 23575079
Cancers (Basel). 2018 Apr 01;10(4):
pubmed: 29614789
Cancer Biol Ther. 2015;16(6):807-20
pubmed: 25894333
Mod Pathol. 2019 Oct;32(10):1495-1507
pubmed: 31186528
Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8568-73
pubmed: 9671718
Am J Surg Pathol. 2015 Jul;39(7):993-9
pubmed: 25786082
Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):13629-34
pubmed: 8942985
J Biol Chem. 2000 Jun 16;275(24):18424-31
pubmed: 10747992
Appl Immunohistochem Mol Morphol. 2017 Jan;25(1):12-24
pubmed: 26371427
Nature. 2012 Aug 23;488(7412):504-7
pubmed: 22820252
Cancer. 2001 Jun 15;91(12):2417-22
pubmed: 11413533
Am J Surg Pathol. 2014 Nov;38(11):1501-9
pubmed: 25229768
Int J Cancer. 2006 Jan 1;118(1):115-22
pubmed: 16003745
Cancer Res. 1998 Nov 15;58(22):5248-57
pubmed: 9823339
Cancer Prev Res (Phila). 2012 Feb;5(2):320-7
pubmed: 22086678
Virchows Arch. 2020 May;476(5):745-752
pubmed: 31811435
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
Oncotarget. 2016 Apr 23;7(23):34546-57
pubmed: 27120810
Br J Cancer. 2002 Aug 12;87(4):400-4
pubmed: 12177776
Cancer Res. 1998 Aug 1;58(15):3455-60
pubmed: 9699680
Br J Cancer. 1999 Apr;80(1-2):11-6
pubmed: 10389971
Nat Med. 1998 Jul;4(7):844-7
pubmed: 9662379
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Br J Cancer. 2005 May 9;92(9):1746-53
pubmed: 15856045
Int J Gynecol Cancer. 2015 Sep;25(7):1165-72
pubmed: 26111272
J Mol Diagn. 2011 May;13(3):271-81
pubmed: 21497289
Hum Vaccin Immunother. 2015;11(12):2790-5
pubmed: 26308285
JCO Precis Oncol. 2017;2017:
pubmed: 29850653
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Diagn Pathol. 2014 Jun 26;9:126
pubmed: 24968821
Pol J Pathol. 2003;54(1):31-7
pubmed: 12817878
Cancer Med. 2018 Mar;7(3):746-756
pubmed: 29436178
Cancers (Basel). 2019 Apr 15;11(4):
pubmed: 30991694
Genetics. 1998 Apr;148(4):1637-46
pubmed: 9560383
World J Urol. 2018 Jun;36(6):877-882
pubmed: 29427004
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
Pancreas. 2014 Nov;43(8):1264-70
pubmed: 25058881
Gynecol Oncol. 2014 Apr;133(1):43-7
pubmed: 24444820
Virchows Arch. 2018 Apr;472(4):653-665
pubmed: 29356891
Cancers (Basel). 2019 Jan 03;11(1):
pubmed: 30609853
Fam Cancer. 2018 Apr;17(2):235-245
pubmed: 28687971
Clin Chem. 2014 Sep;60(9):1192-9
pubmed: 24987110
Clin Cancer Res. 2018 Mar 15;24(6):1326-1336
pubmed: 29367431
Am J Pathol. 2000 May;156(5):1641-51
pubmed: 10793075
J Clin Oncol. 2019 Feb 1;37(4):286-295
pubmed: 30376427
Clin Cancer Res. 2015 Oct 1;21(19):4286-93
pubmed: 25977344
J Clin Oncol. 2011 May 20;29(15):1949-55
pubmed: 21483002
Clin Cancer Res. 2012 Aug 15;18(16):4266-76
pubmed: 22896693
Mod Pathol. 2015 Oct;28(10):1383-9
pubmed: 26226846
Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):178-83
pubmed: 14734467
Am J Surg Pathol. 2016 Jul;40(7):909-16
pubmed: 27186853
N Engl J Med. 2017 Oct 12;377(15):1409-1412
pubmed: 29020592
Clin Cancer Res. 2002 Aug;8(8):2536-40
pubmed: 12171881
J Mol Diagn. 2007 Sep;9(4):472-8
pubmed: 17652638
Fam Cancer. 2014 Mar;13(1):1-12
pubmed: 23880961
Korean J Pathol. 2013 Feb;47(1):28-35
pubmed: 23483099
Gynecol Oncol. 2009 Sep;114(3):486-90
pubmed: 19515405
PLoS Genet. 2017 Apr 19;13(4):e1006739
pubmed: 28422960
Gastroenterology. 2018 Mar;154(4):1061-1065
pubmed: 29158190
Am J Clin Pathol. 2010 May;133(5):772-80
pubmed: 20395525
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Mol Cancer Res. 2018 May;16(5):805-812
pubmed: 29523759
Am J Hum Genet. 2002 Jan;70(1):26-37
pubmed: 11709755
Pathology. 2019 Jan;51(1):110-113
pubmed: 30497803
Nat Med. 2016 Nov;22(11):1342-1350
pubmed: 27694933
Nature. 2015 May 7;521(7550):81-4
pubmed: 25707793